<DOC>
	<DOCNO>NCT00666497</DOCNO>
	<brief_summary>The purpose study determine effective azacitidine , MGCD0103 , combination azacitidine MGCD0103 treat AML MDS people 60 year age .</brief_summary>
	<brief_title>Phase 2 Study Azacitidine ( Vidaza ) v MGCD0103 v Combination Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>This randomize , 3-arm Phase 2 study compare safety efficacy single-agent azacitidine ( currently 1 3 approve treatment myelodysplastic syndrome [ MDS ] ) single-agent MGCD0103 combination therapy MGCD0103 azacitidine elderly patient acute myelogenous leukemia ( AML ) intermediate-2 ( Int-2 ) high-risk MDS , standard care exist . The goal study determine 3 treatment arm worthy investigation subsequent Phase 3 study elderly subject AML Int-2 high-risk MDS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Mocetinostat</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Able provide write informed consent , willing able comply study procedure Must 60 year age old Must pathologic confirmation newly diagnose ( de novo untreated secondary ) AML newly diagnose Int2 highrisk MDS ( IPSS classification ) accord WHO criteria Must Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Must adequate organ function , include total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; AST &amp; ALT ≤ 2.5 x ULN ; serum creatinine ≤ 2.0 x ULN . Considered fit intensive chemotherapy opt treat intensive chemotherapy Prior transplantation prior anticancer therapy ( standard investigational , include chemotherapy , treatment HDAC inhibitor , combination HDAC azacitidine ) administer treat AML MDS . Clinical evidence central nervous system ( CNS ) involvement leukemia A diagnosis promyelocytic leukemia Previous concurrent malignancy except adequately treat basal cell squamous cell skin cancer ; situ carcinoma cervix , solid tumor treat curatively , without evidence recurrence least 3 year prior study entry Active uncontrolled clinically significant infection Known positive serology hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) Less 4 week elapse since major surgery Any prior active disease may interfere procedure evaluation conduct study</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>Vidaza</keyword>
	<keyword>MGCD0103</keyword>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>DNA methyltransferase inhibitor</keyword>
	<keyword>Epigenetic Therapy</keyword>
</DOC>